Form 4: BiomX CFO Marina Wolfson Reports Stock Option Grant

Marina Wolfson, CFO of BiomX Inc., reports the acquisition of 950,000 stock options.

Summary

• On July 11, 2024, Marina Wolfson, the Chief Financial Officer of BiomX Inc., reported the acquisition of 950,000 stock options.
• These options have an exercise price of $0.363.
• The options vest over four years, with 25% vesting on July 11, 2025, and the remainder vesting in 12 equal quarterly installments over three years.
• Following the transaction, Wolfson directly owns 950,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of four years with a one-year cliff (25% vesting after one year) followed by quarterly vesting is a typical arrangement.
• Comparable companies like CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates